ESR1 and neoplasm: In pancreatic cancer, neuroblastoma, colon cancer, and estrogen receptor-positive breast cancer, nomilin has shown significant inhibitory effects on tumor cells proliferation (Poulose et al. 2006; Lam and Hasegawa 1989; Kim et al. 2013).